User: Guest  Login
More Searchfields
Simple search
Title:

Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.

Document type:
Letter; Research Support, Non-U.S. Gov't; Letter
Author(s):
Götze, KS; Hoffmann, D; Schätzl, HM; Peschel, C; Fend, F; Decker, T
Abstract:
We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patient subsequently developed a rapidly fatal Epstein-Barr-virus-associated lymphoproliferative disorder, clonally unrelated to the CLL. The clinical course suggests caution when using...     »
Journal title abbreviation:
Haematologica
Year:
2007
Journal volume:
92
Journal issue:
9
Pages contribution:
1282-3
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/17768130
Print-ISSN:
0390-6078
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Virologie
 BibTeX